[Efficacy, safety, and pharmaco-economical aspects of the therapy for dyslipidemia with brand-name and generic statins].
To compare clinical, cost-effect efficacies and safety of simvastatin Zokor and generic Vasilip in correction of dislipoproteinemia in patients with ischemic heart disease. The original statin Zokor and generic statin Vasilip were given for 8 weeks in a dose 20 mg/day. Vasilip and Zokor demonstrated similar hypolipidemic efficacy and safety, but Vasilip administration was more cost-effective. Simvastatin Vasilip is recommended for wider use in clinical practice because it is clinically and cost effective.